Defying the traditional division between Contract Research Organizations (CRO) and contract development and manufacturing (CDMO), LakePharma has become the first US-based a full-scale Contract Research, Development and Manufacturing Organization (CRDMO) – providing integrated end-to-end services for the biologics development community.

The company, with operations in California, Texas, and Massachusetts, specializes in the production and evaluation of DNA vectors, viral vectors, cell lines, proteins, antibodies, and antibody-drug conjugates. The company also provides integrated solutions bridging discovery, engineering, development, and cGMP manufacturing.

To take the process a step further, the company has formed a strategic alliance with NJ Biopharmaceuticals (NJ Bio) to offer streamlined antibody-drug conjugate (ADC) development solutions.

MabPlex
 

Headquartered in the New Jersey Bioscience Center in North Brunswick, NJ and with additional chemistry facilities in Bristol, PA, and a satellite office in Cambridge, MA, NJ Bio provides integrated chemistry and biology services including bioconjugation, antibody-drug conjugates, multistep organic synthesis, medicinal chemistry, and flow chemistry.

Strength
The strength of the new alliance is based on LakePharma’s 10-year experience as a leading supplier of novel antibodies, while NJ Bio has unique expertise in linker-payload synthesis and bioconjugation for the creation of ADCs.

Under the terms of the alliance, LakePharma will manufacture and provide antibodies as starting materials for ADC development carried out by NJ Bio in a single, seamless workflow for clients, making therapeutic ADC manufacturing from initial antibody discovery to the production of the drug conjugates significantly more efficient both in time and expense.

“LakePharma is an expert in antibody discovery, engineering, and production while NJ Bio is a pioneer in performing chemistries with antibodies. An alliance between these two companies makes perfect sense. Our partnership with NJ Bio allows us to provide a one-stop experience for our contract research partners,” said Hua Tu, Ph.D., Chief Executive Officer and chairman of LakePharma.

“This alliance will expand and add value to the ADC services we currently provide to our clients, creating cost-effective solutions through the provision of complementary service offerings between NJ Bio and LakePharma,” confirmed Nareshkumar Jain, Ph.D., President and Chief Executive Officer of NJ Bio.